Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
Feature|Articles|October 7, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
How QMM Can Help the C-Suite See a $100 Million Problem Early
Author(s)Kamal Biswas
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Advertisement
Advertisement
“Site 7: Supply resilience alert: Management attention recommended.
Related to this article
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Brox.AI’s Hamish Brocklebank on why it retired “digital twin” for “digital clone” — and why the distinction matters for pharma research accuracy.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Advertisement
Advertisement